Key Quantitative Figures

  • Standalone Revenue from Operations: ₹244.34 lakh (FY 2025-2026) vs ₹63.19 lakh (FY 2024-2025)
  • Standalone Net Profit: ₹31.84 lakh (FY 2025-2026) vs Net Loss of ₹4.87 lakh (FY 2024-2025)
  • Paid-up Share Capital: ₹606.34 lakh (60,63,428 equity shares of ₹10 each)
  • Total Assets: ₹1,561.11 lakh as of March 31, 2026
  • Inventory Value: ₹677.06 lakh (unchanged from previous year)
  • Trade Receivables: ₹393.32 lakh
  • Cash & Cash Equivalents: ₹6.37 lakh

Preferential Issue and Variation Proposal

The company had previously received shareholder approval on March 20, 2026 for a preferential issue of 75,00,000 Equity Shares and 50,00,000 Convertible Warrants at ₹20 per share/warrant, aggregating ₹25 crore. The allotment was made on May 5, 2026.

Original Objects vs Revised Objects:

| Original Object | Original Allocation (₹) | Revised Object | Amount Utilized (₹) | Revised Allocation (₹) |

| Plant & Machinery for medicine manufacturing | 15,69,00,000 | Discontinued | Nil | Nil |

| Civil structures | 7,31,00,000 | Discontinued | Nil | Nil |

| Purchase of Land & Building | 1,00,00,000 | No change | 1,00,00,000 | Nil |

| General corporate purposes | 1,00,00,000 | No change | Nil | 1,00,00,000 |

| Not originally envisaged | Nil | Strategic investment in Infuze Well | Nil | 23,00,00,000 |

Total: Original ₹25,00,00,000 → Revised utilization ₹1,00,00,000 with ₹24,00,00,000 balance to be utilized

The variation requires approval through Special Resolution (Item 5 of AGM business).

Strategic Investment in Infuze Well Private Limited

The company proposes to invest up to ₹23 crore by subscribing to 2,30,00,000 freshly issued equity shares of Infuze Well Private Limited (IWPL) at ₹10 per share. This would give Prism Medico a 71.32% stake in IWPL, making it a subsidiary.

Rationale: IWPL is setting up a Large Volume Parenteral (LVP) manufacturing facility at Naraingarh, Haryana with estimated annual capacity of 5.58 crore units. The investment offers a faster route to augment manufacturing capability with lower execution risk than a greenfield project.

Related Party Aspect: IWPL is a related party as Sakshi Laller (Whole-Time Director of Prism Medico) holds 19.40% in IWPL and serves as its Director. Other promoters include Pawan Kumar (24.27%), Manju Rani (27.14%), and Madhu (29.19%).

Financial Impact: The investment will be funded from the preferential issue proceeds, subject to variation approval. The transaction value represents 931.36% of Prism Medico's annual consolidated turnover.

Approvals Required:

  • Special Resolution for investment under Section 186 (Item 6)
  • Ordinary Resolution for related party transaction (Item 7)

Financial Performance Highlights FY 2025-2026

  • Revenue from Operations: ₹244.34 lakh vs ₹63.19 lakh (previous year)
  • Other Income: ₹2.61 lakh
  • Profit Before Tax: ₹42.96 lakh vs Loss of ₹6.58 lakh (previous year)
  • Tax Expense: Deferred tax credit of ₹11.12 lakh
  • Net Profit: ₹31.84 lakh vs Net Loss of ₹4.87 lakh (previous year)
  • EPS: ₹0.53 vs (₹0.08) (previous year)

Board and Committee Composition

Board of Directors:

  • Ms. Sakshi Laller (Whole-Time Director)
  • Mr. Davender Singh (Director)
  • Mr. Dinesh Kumar (Independent Director)
  • Mr. Pardeep Kumar (Independent Director)

Key Managerial Personnel:

  • Mr. Bharat Singh (CFO)
  • Mr. Sameer Gupta (Company Secretary)

Board Meetings: 10 meetings held during FY 2025-2026 with 100% attendance by all directors.

Committee Composition:

  • Audit Committee: Mr. Davender Singh (Chairperson), Mr. Pardeep Kumar, Mr. Dinesh Kumar (8 meetings)
  • Nomination and Remuneration Committee: Same members as Audit Committee (5 meetings)
  • Stakeholder Grievance Committee: Same members as Audit Committee (2 meetings)

Secretarial Audit Report Observations

The Secretarial Audit Report for FY 2025-2026 noted several compliance issues:

  • Late submissions of shareholding pattern (fine ₹7,080 by BSE)
  • Incomplete financial results submission (fine ₹29,500 by BSE)
  • Late submission of integrated governance report (fine ₹17,700 by BSE)
  • Website not fully updated as per Regulation 46 requirements
  • Independent directors don't fully meet eligibility criteria under Rule 6(4) of Companies (Appointment and Qualifications of Directors) Rules, 2014
  • Promoter share acquisition incorrectly classified in shareholding pattern

Management has acknowledged these issues and committed to improved compliance.

AGM Details

Date and Time: September 19, 2026 at 12:30 PM

Mode: Video Conferencing/Other Audio Visual Means

Record Date: September 12, 2026

e-Voting Period: September 16, 2026 (9:00 AM) to September 18, 2026 (5:00 PM)

Business Items:

1. Adoption of financial statements

2. Re-appointment of Mr. Davender Singh as director retiring by rotation

3. Re-appointment of statutory auditors

4. Appointment of secretarial auditors for 5 years

5. Variation of preferential issue objects (Special Resolution)

6. Investment in Infuze Well under Section 186 (Special Resolution)

7. Related party transaction - investment in Infuze Well (Ordinary Resolution)

8. Approval of related party transactions up to ₹70 crore (Ordinary Resolution)

Capital Structure Impact

The proposed investment in Infuze Well will not affect Prism Medico's capital structure as it will be funded from the preferential issue proceeds. The investment will make Infuze Well a subsidiary of Prism Medico.